Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4948322 | 0.87 | TNNI3K (0.45) | TNNI3KPOLBL3MBTL1TDP1EGFR | |
| SCHEMBL14601549 | 0.83 | KAT6A (0.52) | TNNI3KPOLBL3MBTL1TDP1EGFR | |
| SCHEMBL12561642 | 0.77 | KEAP1 (0.62) | TNNI3KL3MBTL1KAT6AALDH1A1LMNA | |
| SCHEMBL29909928 | 0.77 | KEAP1 (0.62) | TNNI3KL3MBTL1KAT6AALDH1A1LMNA | |
| SCHEMBL28468656 | 0.75 | POLB (0.46) | TNNI3KPOLBL3MBTL1TDP1EGFR | |
| SCHEMBL28212268 | 0.75 | FBP1 (0.50) | TNNI3KPOLBL3MBTL1EGFRKAT6A | |
| SCHEMBL13605417 | 0.75 | SLC40A1 (0.54) | TNNI3KL3MBTL1KAT6AFFAR4 | |
| SCHEMBL31310940 | 0.74 | ALDH1A1 (0.60) | TNNI3KPOLBL3MBTL1TDP1EGFR | |
| SCHEMBL21054365 | 0.74 | ALDH1A1 (0.60) | TNNI3KPOLBL3MBTL1TDP1EGFR | |
| SCHEMBL21054362 | 0.74 | ALDH1A1 (0.60) | TNNI3KPOLBL3MBTL1TDP1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | TNNI3K 4183/4885POLB 3890/4885L3MBTL1 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.